Di (hetero) arilciclohexano Derivatives, Preparation method and Pharmaceutical compositions containing same and Uses of same in Cardiac pathologies.

摘要

The compounds of Formula 1 are valuable pharmaceutical compounds that inhibit ATP sensitive potassium channels in the heart, for example, they can be used to treat cardiovascular system disorders, such as arrhythmias or heart failure, such as possible situations, Heart disease, heart disease, or cardiomyopathy. Item 1: a compound of Formula 1, wherein AR1 and ar2 are independent of each other, may be the same or different, be phenyl, naphthalene or isopropyl, and can be replaced with 1, 2, 3 or 4 substitutes that are exactly the same or different from the halogen series,Ciano, C1-5 tar, alquenilo c2-5, cycloquil c3-8-cvh2v, Ar3, c1-5-o -,-5-O---In these substances, all tar, halogenated compounds and cyclopropyl compounds in AR1 and ar2 are replaced by one or more fluorine substitutes; Ar3 and AR5 are independent o f each other and can be the same or different, belonging to phenyl or monocyclic, These alternatives are all optional, consisting of 1, 2 or 3 exactly the same or different halogen, cyanogen, C1-5 tar, c1-5-o --.Oalquil C1-3O alquil C1-5S (O) my R13R14NS (O) 2 en donde todos los grupos alquilo en Ar3 y Ar5 est n opcionalmente sustituidos con uno oms sustituyentes fluor Ar4 es fenilo o heteroarilo que est n todos opcionalmente sustituidos con 1 2 -5-O---C1-3O alkyl, C1-5S alkyl (O) n and R15R16NS (O) 2, wherein all alkyl, alkenyl and cycloalkyl groups in Ar4 are optionally substituted with one or more fluorine substituents; R1 is R3, R4O or R5R6N; R2 is hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C2-8 phenyl-alkenyl, Ar4, R17-O-C1-8 alkyl, R18R19N-C1-8 alkyl, Het-CuH2u or C3 cycloalkyl alkyl -8-CuH2u, wherein the phenyl group in C2-8 phenyl-alkenyl is optionally substituted with 1, 2 or 3 identical or different substituents of the series consisting of halogen, cyano, C1-5 alkyl, C1-5 alkyl- O- and C1-5S alkyl (O) g, and wherein all alkyl groups, alkenyl groups,alkynyl groups and cycloalkyl groups in R2 are optionally substituted with one or more fluorine substituents; R3, R4, R5 and R6, which are all independent of each other and which may be identical or different, are hydrogen, C1-8 alkyl or C3-8-CpH2p cycloalkyl, where all alkyl groups and cycloalkyl groups in R3, R4, R5 and R6 are optionally substituted with one or more fluorine substituents; R11, R12, R13, R14, R15, R16, R17, R18 and R19, which are all independent of each other and can be identical or different, are hydrogen, C1-8 alkyl or C3-8-CqH2q cycloalkyl, where all alkyl groups and cycloalkyl groups in R11, R12, R13, R14, R15, R16, R17,R18 and R19 can be replaced by one or more fluorescent substitutes; het is the residue of a saturated ring composed of four to seven single rings, which contains one or two heterocyclic atoms in a series of nitro, oxygen and sulfur, which are identical or different, and connected together by a cyclic carbon atom, which is optional. 1. 2, 3 or 4 are replaced with the same or different substitutes for C1-5 phenyl and hydrocarbon, wherein the phenyl group in het is replaced with 1, 2 or 3 with the same or different substitutes for halogenated, cyanogen and C1-5 hydrocarbons,C1-5-o - and c1-5-s (o) H tar, in which all tar groups of het and het can be replaced by one or more fluorine substitutes; heteromorphism is the residue of 5 members or 6 single ring aromatic ring systems, or the residue of 1 member in a double ring aromatic ring system composed of 8 members, 9 members or 10 members, 2 or 3 identical or different heterocyclic atoms, consisting of nitro, oxygen and sulfur; F, G, h, K, m and N, independent of each other, may be the same or different, 0, 1 or 2; P, Q, V and W, independent of each other, may be the same or different, 0, 1, 2, 3 or 4; or 0, 1. 2, 3, 4, 5 or 6;In this case, all cyclopropyl compound groups, whether or not there are other substitutes, may choose to use one or more of the same or different C1-4 tar substitutes; in any stereoisomer form or in any way mixed to form an isomer form, Or one of its physiologically acceptable salts; however, if R1 is both hydroxyl and R2 is both hydrogen, AR1 and ar2 should not be substituted for phenyl at the same time.